Who are the key players in North America Antimicrobial Susceptibility Testing Market industry?

The top 5 key players in the North America Antimicrobial Susceptibility Testing Market are bioMérieux SA, Becton, Dickinson and Company, Thermo Fisher Scientific, Danaher Corporation (Beckman Coulter), and Merck KGaA. These companies are leaders in diagnostics and laboratory solutions, delivering innovative testing platforms and expanding their regional presence.

Which segment accounted for the largest North America Antimicrobial Susceptibility Testing Market share?

The diagnostic laboratories segment accounted for the largest market share due to the increased demand for rapid and accurate antimicrobial susceptibility testing across hospitals and reference labs. Growing test volumes and centralized laboratory expansion have bolstered this segment's dominance in managing infectious diseases across North America.

What are the factors driving the North America Antimicrobial Susceptibility Testing Market?

Key drivers include the rising prevalence of infectious diseases, increasing resistance to existing antimicrobials, and strong healthcare infrastructure. Companies like Thermo Fisher Scientific are investing in automation and high-throughput testing platforms, further driving market adoption and accelerating timely disease management.

Which type accounted for the largest North America Antimicrobial Susceptibility Testing Market share?

The manual antimicrobial susceptibility testing type, such as disk diffusion, accounted for the largest share due to its standardized use in clinical laboratories and cost-effectiveness. However, automated systems are rapidly gaining traction, offering improved accuracy and efficiency for high-volume testing environments.

Home Healthcare

North America Antimicrobial Susceptibility Testing Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2035)

Name: North America Antimicrobial Susceptibility Testing Market
Brand: Bussiness Insights

North America Antimicrobial Susceptibility Testing Market: by Type (Disk Diffusion, Rapid Automated, E-test, Broth Dilution, Agar Dilution, Genotypic Methods), Application (Clinical Diagnostics, Drug Discovery and Development, Epidemiology, Veterinary Applications, Environmental Monitoring, Others), Distribution Channels (Direct Tender, Retail Sales, Online Sales, Distributors/Wholesalers, Group Purchasing Organizations, Others), Technology (Molecular Testing, Automated AST, Manual Testing, Spectroscopy-based, Microarrays, Others), Organization Size (Small, Medium, Large) and By North America Historical & Forecast Period (2020-2035) Comprehensive Study 2025

Last Updated: 31-07-2025 | Format: PDF | Report ID:20279 | Author: Sophia

RD TOC Segmentation Research Methodology Request For Free Sample Copy

North America Antimicrobial Susceptibility Testing Market Analysis and Forecast (2020-2035)

The North America antimicrobial susceptibility testing (AST) market is set for robust growth through 2035, driven by increasing antimicrobial resistance, advanced diagnostic technologies, and regulatory initiatives supporting rapid AST adoption. The market comprises diverse testing methods such as disk diffusion, automated AST, and molecular testing, with clinical diagnostics and drug discovery as key application areas. The sector is highly competitive with major companies focusing on innovation, partnerships, and regional expansion to enhance their market presence.

Latest Market Dynamics

Key Drivers

Rising prevalence of antimicrobial-resistant infections is propelling the demand for advanced and rapid AST solutions across North America. For instance, in June 2024, bioMérieux SA launched a next-gen rapid AST system enabling faster clinical decision-making in major US hospitals.

Accelerated digitalization and adoption of automated AST platforms are streamlining laboratory workflows, reducing turnaround times. BD (Becton, Dickinson and Company) announced its expanded portfolio of automated AST solutions in August 2024, emphasizing rapid result generation.
Integration of molecular testing with conventional AST methods is gaining momentum, driven by rising demand for comprehensive, rapid diagnostics. Danaher Corporation enhanced its Genotypic Methods offering in September 2024 through acquisition of a leading molecular diagnostics startup.

Expanding use of AST in environmental monitoring and veterinary applications is opening new avenues for market players. In June 2024, Merck KGaA partnered with US-based environmental labs to deploy AST solutions for water safety monitoring.
Growing investments in public-private partnerships and research funding are fueling new product developments in AST. In August 2024, Accelerate Diagnostics, Inc. secured federal funding aimed at developing next-generation rapid AST technology platforms.

High costs associated with adoption of automated and molecular AST technologies present a challenge for smaller labs and facilities. Creative Diagnostics addressed this by launching a cost-effective semi-automated AST system in July 2024.
Stringent regulatory requirements and complex approval processes for new AST devices continue to slow market entry. Bio-Rad Laboratories, Inc. faced delayed product clearance for its novel AST system, impacting its 2024 rollout strategy.

Limited awareness and lack of trained professionals for advanced AST techniques, particularly in rural and small healthcare settings. Sekisui Diagnostics initiated a training program in August 2024 to mitigate this barrier.
Potential for diagnostic errors and inconsistent test outcomes due to variability in manual AST testing methods. Liofilchem Srl is addressing this by offering standardized, high-reproducibility AST consumables since June 2024.

In 2025, disk diffusion remains the most utilized AST type, followed by rapid automated solutions and broth dilution. Disk diffusion’s widespread adoption is attributed to cost-effectiveness and established use in clinical laboratories. However, rapid automated AST is experiencing the fastest growth, fueled by the need for efficient and scalable testing in hospital settings. Broth dilution and genotypic methods are gaining traction for their precision and ability to provide detailed susceptibility profiles, especially for complex pathogens.

Clinical diagnostics accounts for the dominant share in AST applications in North America (2025), followed by drug discovery & development and epidemiology. The region’s high incidence of hospital-acquired infections and strong emphasis on infection control drive usage in clinical diagnostics. Drug discovery leverages AST for new compound screening, while epidemiological applications are growing due to heightened public health surveillance and tracking of resistance patterns. Additional expansion is seen in veterinary and environmental testing, reflecting the broader impact of antimicrobial resistance.

The North America AST market registered a revenue of 1,038 million USD in 2025, projected to climb steadily through 2035. Rising investments in healthcare infrastructure, emphasis on rapid diagnostics, and regulatory mandates for AST in infection control protocols are contributing to sustained market growth. Forecasts indicate continued double-digit CAGR, with market value expected to surpass 2,800 million USD by 2035 as modernization and adoption of automated and molecular testing platforms accelerate across healthcare and allied segments.

Year-over-year growth in the North America AST market remains robust through 2035, peaking at 7.5% in 2025. Growth rates reflect surges in adoption of digital and AI-driven testing platforms, strengthened pandemic preparedness measures, and ongoing investments in laboratory capabilities. While YOY percentage growth moderates slightly post-2030 as the market matures, strong adoption trends persist due to regulatory requirements and innovation cycles.

In 2025, the United States dominates the North America AST market with a 66% share, propelled by its advanced healthcare infrastructure, stringent clinical guidelines, and leadership in diagnostic innovation. Canada follows at 21%, leveraging robust research networks and public health focus, while Mexico’s 13% share is characterized by growing investments in hospital modernization and infectious disease management. Collectively, North America epitomizes a high adoption environment for AST technologies.

bioMérieux SA holds the leading share of the North America AST market at 19% in 2025, followed by BD (Becton, Dickinson and Company) at 17% and Thermo Fisher Scientific Inc. at 14%. Other prominent players such as Danaher Corporation and Bruker Corporation command significant shares due to robust product portfolios and aggressive R&D. Intense competition and continuous innovation characterize the player landscape, with collaborative ventures and mergers shaping market trajectories.

Hospitals and clinical laboratories account for the largest share of AST market buyers at 57% in 2025, highlighting their central role in patient management and infection control. Pharmaceutical & biotechnology firms hold a 20% share, utilizing AST in drug discovery pipelines. Public health agencies, veterinary clinics, and environmental labs represent the remainder, reflecting diversification of market demand driven by the fight against antimicrobial resistance.

Metrics	Details
Years	2020-2035
Base Year	2025
Market Size	1038
Regions	United States, Canada, Mexico
Segments	By Type (Disk Diffusion, Rapid Automated AST, E-test, Broth Dilution, Agar Dilution, Genotypic Methods), By Application (Clinical Diagnostics, Drug Discovery and Development, Epidemiology, Veterinary Applications, Environmental Monitoring, Others), By Distribution Channels (Direct Tender, Retail Sales, Online Sales, Distributors/Wholesalers, Group Purchasing Organizations, Others), By Technology (Molecular Testing, Automated AST, Manual Testing, Spectroscopy-based, Microarrays, Others), By Organization Size (Small, Medium, Large)
Players	bioMérieux SA, Becton Dickinson and Company (BD), Thermo Fisher Scientific Inc., Danaher Corporation, Bruker Corporation, Creative Diagnostics, Bio-Rad Laboratories Inc., Accelerate Diagnostics Inc., Hardy Diagnostics, Sekisui Diagnostics, Liofilchem Srl, Merck KGaA, ELITechGroup, HiMedia Laboratories Pvt. Ltd., Vela Diagnostics

June 2024 – bioMérieux SA launches VITEK AST Gen3 platform for ultra-rapid automated bacterial identification and susceptibility profiling in US hospitals.
July 2024 – Thermo Fisher Scientific Inc. unveils cloud-integrated, AI-enabled AST solution enabling remote clinical decision support.
August 2024 – BD introduces Presto AST Full Automation Module, cutting lab workflow times by 30% in flagship diagnostic centers.
August 2024 – Accelerate Diagnostics, Inc. secures US$37 million federal grant for next-generation rapid AST development.
September 2024 – Danaher Corporation acquires PathoMole, strengthening its molecular and genotypic AST technology pipeline.

About the Author

Sophia

Lead Industry Analyst

Sophia is a Lead Industry Analyst specializing in market research, industry analysis, and business consulting across Healthcare. Sophia brings a commercially grounded perspective to sectors shaped by changing demand, innovation, and competitive dynamics, helping turn complex market trends into clear strategic insights for business decision-makers. With 10+ years of experience across research, analytics, and strategic advisory roles, Sophia has helped organizations translate data into actionable growth strategies.

HealthcareMarket ResearchIndustry AnalysisStrategic Consulting

Key Questions Answered

»What is the market size and growth rate of the global and regional market by various segments?
»What is the market size and growth rate of the market for selective countries?
»Which region or sub-segment is expected to drive the market in the forecast period?
»What factors are estimated to drive and restrain the market growth?
»What are the key technological and market trends shaping the market?
»What are the key opportunities in the market?
»What are the key companies operating in the market?
»Which company accounted for the highest market share?

Download Sample

Why Choose Bussiness Insights?

»Strong Industry Focus
»Extensive Product Offerings
»Customer Research Services
»Robust Research Methodology
»Comprehensive Reports
»Latest Technological Developments
»Value Chain Analysis
»Potential Market Opportunities
»Growth Dynamics
»Quality Assurance
»Post-sales Support
»Regular Report Updates

Speak to Analyst

North America Antimicrobial Susceptibility Testing Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2035)

North America Antimicrobial Susceptibility Testing Market Analysis and Forecast (2020-2035)

Latest Market Dynamics

Key Drivers

Key Trends

Key Opportunities

Key Challenges

Key Restraints

North America Antimicrobial Susceptibility Testing Market Share by Type, 2025

North America Antimicrobial Susceptibility Testing Market Share by Applications, 2025

North America Antimicrobial Susceptibility Testing Market Revenue (USD Million), 2020-2035

North America Antimicrobial Susceptibility Testing Market Year-on-Year Growth (%), 2020-2035

North America Antimicrobial Susceptibility Testing Market by Region Share (%), 2025

North America Antimicrobial Susceptibility Testing Market Players Share (%), 2025

North America Antimicrobial Susceptibility Testing Market Buyers Share (%), 2025

Study Coverage

Key Recent Developments

Frequently Asked Questions

About the Author

Related Reports